Industry News

Laser platform for glaucoma, cataract treatment receives CE mark

The Optimis Fusion integrated laser platform from Quantel Medical has been granted a CE mark, according to a press release.

The system has the capability to perform both selective laser trabeculoplasty photoregeneration therapy and traditional YAG photodisruption treatments, the release said.

Quantel plans to begin commercialization in all CE mark-approved countries immediately. Meanwhile, U.S. Food and Drug Administration approval is expected this year, according to the release.

The Optimis Fusion integrated laser platform from Quantel Medical has been granted a CE mark, according to a press release.

The system has the capability to perform both selective laser trabeculoplasty photoregeneration therapy and traditional YAG photodisruption treatments, the release said.

Quantel plans to begin commercialization in all CE mark-approved countries immediately. Meanwhile, U.S. Food and Drug Administration approval is expected this year, according to the release.